These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1335102)

  • 21. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial.
    Paya CV; Wilson JA; Espy MJ; Sia IG; DeBernardi MJ; Smith TF; Patel R; Jenkins G; Harmsen WS; Vanness DJ; Wiesner RH
    J Infect Dis; 2002 Apr; 185(7):854-60. PubMed ID: 11920308
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of prophylactic ganciclovir on cytomegalovirus infection in renal transplant recipients.
    Rondeau E; Bourgeon B; Peraldi MN; Lang P; Buisson C; Schulte KM; Weill B; Sraer JD
    Nephrol Dial Transplant; 1993; 8(9):858-62. PubMed ID: 8255520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early and delayed onset cytomegalovirus infection of liver transplant recipients in endemic areas.
    Kim JM; Kim SJ; Joh JW; Kwon CH; Shin M; Kim EY; Moon JI; Jung GO; Choi GS; Lee SK
    Transplant Proc; 2010 Apr; 42(3):884-9. PubMed ID: 20430197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The risk factors for cytomegalovirus syndrome and tissue-invasive cytomegalovirus disease in liver transplant recipients who have cytomegalovirus antigenemia.
    Kim JM; Kim SJ; Joh JW; Shin M; Moon JI; Jung GO; Choi GS; Kwon CH; Lee SK
    Transplant Proc; 2010 Apr; 42(3):890-4. PubMed ID: 20430198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changing impact of cytomegalovirus in liver transplantation -- a single centre experience of more than 1000 transplantations without ganciclovir prophylaxis.
    Seehofer D; Rayes N; Neumann UP; Meisel H; Oettle H; Nüssler NC; Jonas S; Langrehr JM; Neuhaus P
    Transpl Int; 2005 Aug; 18(8):941-8. PubMed ID: 16008744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factors of cytomegalovirus infection after living donor liver transplantation.
    Akamatsu N; Sugawara Y; Kaneko J; Kishi Y; Makuuchi M
    Hepatogastroenterology; 2005; 52(61):197-9. PubMed ID: 15783029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytomegalovirus infection in renal transplant recipients.
    Carstens J; Andersen HK; Spencer E; Madsen M
    Transpl Infect Dis; 2006 Dec; 8(4):203-12. PubMed ID: 17116133
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients.
    von Bueltzingsloewen A; Bordigoni P; Witz F; Bene MC; Schmitt C; Lacour B; Sommelet D
    Bone Marrow Transplant; 1993 Sep; 12(3):197-202. PubMed ID: 8241976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytomegalovirus infection in heart transplant recipients is associated with impaired endothelial function.
    Petrakopoulou P; Kübrich M; Pehlivanli S; Meiser B; Reichart B; von Scheidt W; Weis M
    Circulation; 2004 Sep; 110(11 Suppl 1):II207-12. PubMed ID: 15364864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pre-transplant risk factors predicting post-transplant cytomegalovirus infection in liver transplant recipients.
    Saito T; Egawa H; Kudo T; Takakura S; Fujihara N; Iinuma Y; Ichiyama S
    Transpl Int; 2007 May; 20(5):419-24. PubMed ID: 17313448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cytomegalovirus infection and disease in pediatric solid organ transplantation. Experience in a Chilean multiorganic transplantation center].
    Salazar E MP; Alba G A; Deluchi B A; Hunter M B; Godoy L J; Ferrario B M; Uribe M M; Buckel G E
    Rev Chilena Infectol; 2009 Aug; 26(4):311-7. PubMed ID: 19802397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recurrent cytomegalovirus disease, visceral leishmaniosis, and Legionella pneumonia after liver transplantation: a case report.
    Halkic N; Ksontini R; Scholl B; Blanc C; Kovacsovics T; Meylan P; Muheim C; Gillet M; Mosimann F
    Can J Anaesth; 2004 Jan; 51(1):84-7. PubMed ID: 14709468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland.
    George MJ; Snydman DR; Werner BG; Griffith J; Falagas ME; Dougherty NN; Rubin RH
    Am J Med; 1997 Aug; 103(2):106-13. PubMed ID: 9274893
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary cytomegalovirus infection in liver transplant recipients: comparison of infections transmitted via donor organs and via transfusions. Boston Center for Liver Transplantation CMVIG Study Group.
    Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG
    Clin Infect Dis; 1996 Aug; 23(2):292-7. PubMed ID: 8842266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3.
    Hibberd PL; Tolkoff-Rubin NE; Cosimi AB; Schooley RT; Isaacson D; Doran M; Delvecchio A; Delmonico FL; Auchincloss H; Rubin RH
    Transplantation; 1992 Jan; 53(1):68-72. PubMed ID: 1310173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation.
    Portela D; Patel R; Larson-Keller JJ; Ilstrup DM; Wiesner RH; Steers JL; Krom RA; Paya CV
    J Infect Dis; 1995 Apr; 171(4):1014-8. PubMed ID: 7706779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary and secondary cytomegalovirus infection.
    Suwansirikul S; Rao N; Dowling JN; Ho M
    Arch Intern Med; 1977 Aug; 137(8):1026-9. PubMed ID: 195547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The potential role of pre-transplant HBcIgG seroposivity as predictor of clinically relevant cytomegalovirus infection in patients with lymphoma undergoing autologous hematopoietic stem cell transplantation: a study from the Rome Transplant Network.
    Marchesi F; Giannotti F; Avvisati G; Petti MC; Pimpinelli F; Paba P; Dessanti ML; Cerretti R; Tirindelli MC; Picardi A; D'Andrea M; Spadea A; Ensoli F; Perno CF; Mengarelli A; Arcese W
    Am J Hematol; 2012 Feb; 87(2):213-7. PubMed ID: 22076952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors associated with cytomegalovirus infection in heart transplant patients: a prospective, epidemiological study.
    Delgado JF; Manito N; Almenar L; Crespo-Leiro M; Roig E; Segovia J; Vázquez de Prada JA; Lage E; Palomo J; Campreciós M; Arizón JM; Rodríguez-Lambert JL; Blasco T; de la Fuente L; Pascual D; Rábago G
    Transpl Infect Dis; 2011 Apr; 13(2):136-44. PubMed ID: 21040280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytomegalovirus disease after liver transplantation: a nationwide population-based study.
    Liu PY; Cheng SB; Lin CC; Lin CH; Chang SN; Cheng CY; Shi ZY; Tung KC; Wu MJ
    Transplant Proc; 2014 Apr; 46(3):832-4. PubMed ID: 24767359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.